MET amplification

3 · 20 / page

Ask MedXY AI

Latest news

Tag

newsMET amplificationNSCLC

Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial

By MedXY|Mar 2, 2026

The Phase 3 SACHI trial demonstrates that the combination of savolitinib and osimertinib significantly extends progression-free survival compared to chemotherapy in patients with MET-amplified, EGFR-mutated non-small-cell lung cancer who pr

Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC

newsMET amplificationNSCLC

MET amplification

Latest news

Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial

Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC

Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study